These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 6616602)

  • 21. Dihydroergotamine nasal spray during migraine attacks. A double-blind crossover study with placebo.
    Tulunay FC; Karan O; Aydin N; Culcuoglu A; Guvener A
    Cephalalgia; 1987 Jun; 7(2):131-3. PubMed ID: 3301001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dihydroergotamine: role in the treatment of migraine.
    Schürks M
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1141-8. PubMed ID: 19624283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between the venoconstrictor activity of dihydroergotamine and its pharmacokinetics during acute and chronic oral dosing.
    de Marées H; Welzel D; de Marées A; Klotz U; Tiedjen KU; Knaup G
    Eur J Clin Pharmacol; 1986; 30(6):685-9. PubMed ID: 3533566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine.
    Aurora SK; Silberstein SD; Kori SH; Tepper SJ; Borland SW; Wang M; Dodick DW
    Headache; 2011 Apr; 51(4):507-17. PubMed ID: 21457235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new technique for recording compliance of human hand veins.
    Aellig WH
    Br J Clin Pharmacol; 1981 Mar; 11(3):237-43. PubMed ID: 7213525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced serotonin vascular sensitivity in ergotamine abusers.
    Panconesi A; Franchi G; Del Bianco PL; Anselmi B; Andreini R; Sicuteri F
    Cephalalgia; 1989 Dec; 9(4):259-64. PubMed ID: 2611883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological actions of the main metabolites of dihydroergotamine.
    Müller-Schweinitzer E
    Eur J Clin Pharmacol; 1984; 26(6):699-705. PubMed ID: 6489409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of transformed refractory migraine with intravenous dihydroergotamine].
    Cid C; Ortega-Valín F; Valero M; Muñoz R; Pascual J
    Neurologia; 1999; 14(6):315-8. PubMed ID: 10439626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Migraine: dihydroergotamine nasal spray--an alternative].
    Beubler E
    Wien Med Wochenschr; 1995; 145(14):326-31. PubMed ID: 7483646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo pharmacodynamic interactions between two drugs used in orthostatic hypotension--midodrine and dihydroergotamine.
    Jourdan G; Verwaerde P; Pathak A; Tran MA; Montastruc JL; Senard JM
    Fundam Clin Pharmacol; 2007 Feb; 21(1):45-53. PubMed ID: 17227444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Timed-release dihydroergotamine in the prophylaxis of mixed headache. A study versus amitriptyline.
    Bonuso S; Di Stasio E; Barone P; Steardo L
    Cephalalgia; 1983 Aug; 3 Suppl 1():175-8. PubMed ID: 6352047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dihydroergotamine increases the bioavailability of orally administered etilefrine.
    Hengstmann JH; Hengstmann R; Schwonzen S; Dengler HJ
    Eur J Clin Pharmacol; 1982; 22(5):463-7. PubMed ID: 6126364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is orally inhaled dihydroergotamine (DHE) equivalent in efficacy in migraine to intravenous DHE?
    Tfelt-Hansen P
    Headache; 2014 Feb; 54(2):383. PubMed ID: 24512579
    [No Abstract]   [Full Text] [Related]  

  • 34. Amplifying effect of sumatriptan on noradrenaline venoconstriction in migraine patients.
    Panconesi A; Franchi G; Anselmi B; Curradi C; Tarquini B
    Cephalalgia; 1993 Dec; 13(6):383-8. PubMed ID: 8313451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Venous tonus-modifying effect, pharmacokinetics and undesired effects of dihydroergotamine].
    Barthel W
    Z Gesamte Inn Med; 1984 Sep; 39(17):417-28. PubMed ID: 6390997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological profile of the inhibition by dihydroergotamine and methysergide on the cardioaccelerator sympathetic outflow in pithed rats.
    Lozano-Cuenca J; Muñoz-Islas E; González-Hernández A; Centurión D; Cobos-Puc LE; Sánchez-López A; Pertz HH; Villalón CM
    Eur J Pharmacol; 2009 Jun; 612(1-3):80-6. PubMed ID: 19356724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Classification, pathogenesis and drug therapy of migraine and related forms of headache].
    Fanchamps A
    Med Welt; 1975 Aug; 6(35):1518-23. PubMed ID: 241000
    [No Abstract]   [Full Text] [Related]  

  • 38. Dihydroergotamine and sumatriptan in isolated human coronary artery, middle meningeal artery and saphenous vein.
    Labruijere S; Chan KY; de Vries R; van den Bogaerdt AJ; Dirven CM; Danser AJ; Kori SH; MaassenVanDenBrink A
    Cephalalgia; 2015 Feb; 35(2):182-9. PubMed ID: 25078720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine.
    Silberstein S
    Expert Opin Pharmacother; 2012 Sep; 13(13):1961-8. PubMed ID: 22860628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interactions of dihydroergotamine with etilefrine in human leg veins in vitro and in situ.
    Barthel W; Glusa E; Koth W
    Int J Clin Pharmacol Ther Toxicol; 1987 Feb; 25(2):63-9. PubMed ID: 2881898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.